All the Drug Class Drugs
Phosphate Binder. Lanthanum 500, 750, 1000 mg. CHEW. TABS: 90 x 500, 750, 1000 mg. See lit.
Phosph. bind. agent in control
hyperphosphatem. in CRP pts. on
hemodialysis/CAPD.
C/I: Hypersens., hypophosphatem.,
pregn., lact.
Phosphate Binder. Lanthanum 750 mg, 1000 mg. SACHET. (pwdr.): 90 x750 mg, 1000mg. See lit.
Phosph. bind. agent in control
hyperphosphatem. in CRP pts. on
hemodialysis/CAPD.
C/I: Hypersens., hypophosphatem.,
pregn., lact.
Phosphate Binder. Sevelamer Carbonate (anhydrous) 800 mg. F.C. TABS: 180 x 800 mg. Initial: 2.4 g/4.8 g 3 x dly with meals, depend. on clin. needs/serum phos. level.
Control hyperphosphatem. in adults
receiv. hemodiaysis/peritoneal dialysis.
Control hyperphosphatem. in chron.
kidney dis. not on dialysis with serum
phos. >1.78 mmol/l. Prevent. renal bone
dis., incl. calcium supplement & 1.25
dihydroxy vit D3. See lit.
C/I: Hypersens., hypophosphatem.,
bowel obstruct.
Phosphate Binder. Sevelamer Carbonate (anhydrous) 2.4 g/Sachet. SACHETS (pwdr. for oral susp.): 2.4 g. Initial: 2.4 g/4.8 g 3 x dly with meals, depend. on clin. needs/serum phos. level.
Control hyperphosphatem. in adults
receiv. hemodiaysis/peritoneal dialysis.
Control hyperphosphatem. in chron.
kidney dis. not on dialysis with serum
phos. >1.78 mmol/l. Prevent. renal bone
dis., incl. calcium supplement & 1.25
dihydroxy vit D3. See lit.
C/I: Hypersens., hypophosphatem.,
bowel obstruct.
Phosphate Binder. Sevelamer Carbonate 800 mg. F.C. TABS.: 160.
The recommended starting dose of sevelamer carbonate is 2.4 g or 4.8 g per day based on clinical needs and serum phosphorus level. See lit.
For the control of hyperphosphataemia in adult pts. receiv. haemodialysis or peritoneal dialysis. Also for the control of hyperphosphataem. in adult pts. with chron. Ren. dis. not on dialys. with serum phosphorus ≥ 1.78 mmol/l.Should be used within the context of a multiple therap. approach, which could includ. calcium supplem. , 1,25-dihydroxy Vitamin D3 or one of its analogues to control the develop. of ren. bone dis.
C/I: Hypersens. Hypophosphataemia. Bowel obstruct.
Phosphate Binder. Sucroferric Oxyhydroxide 500 mg. CHEW. TABS.: 90. Init. dose 1,500 mg iron (3 tabs.)/d, divided across the meals of the day., must be taken with meals.
Pts. receiving should adhere to their prescribed diets.
Titrat.& mainten.: Serum phosphorus levels must be monit. and the dose up or down titrated in increm. of 500 mg iron (1 tab.)/d every 2-4 wks. until an accept. serum phosphorus level is reached, with regular monitor. afterwards.
In clinical practice, tmt. will be based on the need to control serum phosphorus levels, though pts. who respond to drug therapy usually achieve optimal serum phosphorus levels at doses of 1,500 mg-2,000 mg iron/d (3 - 4 tablets). See Lit.
Indicated for the control of serum phosphorus levels in adult chron. kidney dis. (CKD) pts. on haemodialys. (HD) or periton. dialys. (PD). The drug should be used within the context of a multiple therapeut. approach, which could include calcium supplem., 1,25-dihydroxy vitamin D3 or one of its analog., or calcimimetics to control the develop. of renal bone dis.
C/I: Hypersens. Haemochromatosis and any other iron accumulat. disord.
